Equities Analysts Offer Predictions for OKUR Q1 Earnings

OnKure Therapeutics (NASDAQ:OKUR) – Stock analysts at HC Wainwright reduced their Q1 2025 earnings estimates for OnKure Therapeutics in a research note issued on Tuesday, March 18th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($1.41) per share for the quarter, down from their previous estimate of ($1.19). HC Wainwright currently has a “Buy” rating and a $34.00 price target on the stock. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.05) per share. HC Wainwright also issued estimates for OnKure Therapeutics’ Q2 2025 earnings at ($1.43) EPS, Q3 2025 earnings at ($1.27) EPS, Q4 2025 earnings at ($1.15) EPS and FY2025 earnings at ($5.20) EPS.

Several other research analysts also recently commented on the stock. Leerink Partnrs upgraded shares of OnKure Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Oppenheimer dropped their price objective on OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a research report on Tuesday, March 11th. Finally, Leerink Partners started coverage on OnKure Therapeutics in a research report on Thursday, December 5th. They issued an “outperform” rating and a $33.00 target price on the stock. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, OnKure Therapeutics presently has a consensus rating of “Buy” and an average target price of $32.33.

OnKure Therapeutics Stock Up 1.8 %

Shares of NASDAQ:OKUR opened at $5.00 on Thursday. The firm has a market cap of $67.18 million, a PE ratio of -0.41 and a beta of 0.28. The firm has a 50 day moving average price of $5.54. OnKure Therapeutics has a 12 month low of $4.45 and a 12 month high of $20.00.

OnKure Therapeutics (NASDAQ:OKUR) last posted its quarterly earnings results on Monday, March 10th. The company reported ($1.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.51).

Institutional Trading of OnKure Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vestal Point Capital LP purchased a new position in shares of OnKure Therapeutics during the fourth quarter valued at approximately $5,461,000. Two Sigma Advisers LP purchased a new position in OnKure Therapeutics during the 4th quarter worth $122,000. Tang Capital Management LLC bought a new stake in shares of OnKure Therapeutics in the 4th quarter worth $2,534,000. Shay Capital LLC bought a new position in shares of OnKure Therapeutics during the fourth quarter valued at about $129,000. Finally, Sphera Funds Management LTD. purchased a new position in OnKure Therapeutics during the fourth quarter worth about $751,000. Institutional investors own 90.98% of the company’s stock.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.